Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity.
Although antiangiogenic treatment for malignant glioma using bevacizumab in combination with irinotecan chemotherapy has a promising effect on survival, the high incidence of increasing infiltrative tumors can be a problem in resistance to antiangiogenic therapy. In this study, we detected failure of bevacizumab treatment for malignant glioma through upregulation of metalloproteinase activity in the urine, as well as infiltrative tumors on MRI. In addition, MMP9 has been proved as a molecule that facilitates its infiltrative behavior in vivo in the brain animal model.
Department of Neurosurgery, Institute of Clinical Medicine, Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. shingo4@md.tsukuba.ac.jp
Shingo
S
Takano
Ryota
R
Mashiko
Satoru
S
Osuka
Eiichi
E
Ishikawa
Osamu
O
Ohneda
Akira
A
Matsumura
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000097:blood; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000652:urine; D054377:Chemokine CXCL12 / Q000097:blood; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D008279:Magnetic Resonance Imaging; D020780:Matrix Metalloproteinase 9 / Q000097:blood; D020782:Matrix Metalloproteinases / Q000652:urine*; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D017211:Treatment Failure
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D054377:Chemokine CXCL12; D000068258:Bevacizumab; D020782:Matrix Metalloproteinases; D020780:Matrix Metalloproteinase 9